Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
NCT05495828 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2023-10-26
Summary
To evaluate the safety and effecacy of Orelabrutinib therapy in patients with relapsed or refractory B-cell lymphoma (including R /rCLL/SLL and R /rMCL) who are intolerant to ibrutinib/zanubrutinib or other BTK inhibitors
Conditions
Interventions
- DRUG
-
Orelabrutinib
Orelabrutinib, 150mg, po, qd
Sponsors & Collaborators
-
Peking University People's Hospital
lead OTHER
Principal Investigators
-
Shenmiao Yang · Peking University People's Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-11-10
- Primary Completion
- 2024-12-10
- Completion
- 2025-03-10
Countries
- China
Study Locations
More Related Trials
-
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
NCT05926427 ·Status: RECRUITING ·Phase: PHASE2
-
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
NCT04989621 ·Status: RECRUITING ·Phase: PHASE2
-
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
NCT07078500 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma
NCT05234684 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
NCT03189524 ·Status: COMPLETED ·Phase: PHASE1
-
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
NCT05051891 ·Status: COMPLETED ·Phase: PHASE3
-
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02077166 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
NCT01980628 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
NCT05381506 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
NCT05097443 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
NCT03145064 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
NCT06082102 ·Status: RECRUITING ·Phase: PHASE3
-
Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)
NCT05549284 ·Status: RECRUITING ·Phase: PHASE2
-
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
NCT03520920 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
NCT02981745 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas
NCT05113069 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
The Study of ICP-248 in Patients With Mature B-cell Malignancies
NCT05728658 ·Status: RECRUITING ·Phase: PHASE1
-
Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL
NCT06890585 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
NCT05200312 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
NCT01855750 ·Status: COMPLETED ·Phase: PHASE3
-
Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma
NCT05334238 ·Status: UNKNOWN ·Phase: PHASE3
-
Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
NCT02055924 ·Status: TERMINATED ·Phase: PHASE1
-
Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma
NCT06251180 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
NCT03876028 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
NCT02991638 ·Status: UNKNOWN ·Phase: PHASE3